Zelira Therapeutics (AU:ZLD) has released an update.
Zelira Therapeutics, a global biopharmaceutical company specializing in cannabinoid-based medicines, has announced its AGM to be held on November 14, 2024, with a deadline for director nominations on September 26, 2024. The company has recently made advances in clinical development, including a successful study against diabetic nerve pain and is expanding commercialization of its proprietary revenue-generating products. Zelira is also exploring the commercialization of its newly developed EDCDM technology for pharmaceutical-grade oral dosage forms.
For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.
